CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CRISPR Therapeutics AG (CRSP) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, insider selling trends, disappointing financial performance, and a lack of immediate positive catalysts. While analysts maintain a generally positive outlook with reduced price targets, the current market conditions and financial underperformance suggest holding off on investment until clearer growth signals emerge.
The technical indicators for CRSP are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 42.744, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 49.585, with key support at 46.41 and resistance at 52.759. Overall, the technical setup does not indicate a favorable entry point.
Despite disappointing earnings, there is speculation about a potential takeover, which could drive future interest. Additionally, CRISPR holds a strong cash position of $1,975.8 million, providing financial stability for future R&D and operations.
The company reported a significant Q4 revenue decline of 97.6% year-over-year, missing expectations by $3.16 million. Insiders have been selling shares, with a 1518.79% increase in selling activity over the last month. Technical indicators are bearish, and the stock is projected to decline further in the short term. No recent congress trading data or strong proprietary trading signals are available to suggest a buying opportunity.
CRISPR Therapeutics AG reported a Q4 GAAP EPS loss of -$1.37, missing estimates by $0.22. Revenue dropped to $0, down 100% YoY, while net income improved to -$130.6 million, up 250.07% YoY. The company has a strong cash position, increasing to $1,975.8 million from $1,903.8 million the previous year, but gross margin dropped to 0, down 100% YoY. Overall, the financial performance is weak, with limited revenue generation and ongoing losses.
Analysts maintain a generally positive outlook with Buy or Outperform ratings, but price targets have been reduced recently. The latest target from Citizens is $80, down from $86, while BofA lowered its target to $89 from $90. Analysts acknowledge the potential for late-stage development in multiple opportunities by 2027, but much of the pipeline opportunity is not currently reflected in the valuation.
